FIG. 1.
Development of a stable therapeutic lead on the structural basis of compound AM-4. (A) AM-4 has a short half-life under physiological conditions. Serial dilutions of compound in growth medium were preincubated at 37°C as indicated, followed by transfer to cells and infection with MV. Virus yields were determined by TCID50 titration and are expressed in percentages of control cells infected in the presence of 0.01% DMSO. Values represent averages of two experiments performed in duplicate each. Standard deviations are shown. (B) Structure of AM-4. (C) Structure template of AM-4 used for structure-activity relationship development. (D) Structure of the improved lead compound AS-48.